October 3, 2024 02:50 PM EDT
People
R&D

Ex­clu­sive: Re­lay Ther­a­peu­tics cuts an­oth­er 10% of com­pa­ny, cit­ing con­tin­ued stream­lin­ing ef­forts

Max Bayer

Pharma Reporter

Re­lay Ther­a­peu­tics is lay­ing off 10% of its staff, or about 30 em­ploy­ees, in an ad­di­tion­al round of job cuts af­ter a small­er down­siz­ing in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times